spacer
home > pmps > spring 2007 > lyophilisation closures
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Lyophilisation Closures

With no universal lyophilisation closure on the market, Douglas Cusato at Helvoet Pharma reiterates the importance of compendial, functional and stability tests

LYOPHILISED PHARMACEUTICALS

During the design of modern day pharmaceuticals, researchers have to consider a wide range of variables. A simple variable that needs to be considered is the colour of products and their packaging components for identification and marketing. One of the more difficult variables is the type of closure system a product will be packaged in, and how it will be administered. However, most modern day protein/peptide-based pharmaceuticals have been mainly confined to lyophilisation packaging systems. This is due to proteinís inability to maintain a suitable shelf-life in other pharmaceutical packaging environments, such as aqueous mediums in prefilled syringes and vials. Furthermore, oral administration of protein-based pharmaceuticals is not accomplishable, due to the extremely high acidic environment of the stomach.

LYOPHILISATION CLOSURES

Historically, the function of rubber closures was limited to maintaining a seal in the vial or barrel opening, confining a pharmaceutical within a vial or prefilled syringe and permitting proper removal of the pharmaceutical via a hypodermic needle. More recently the rubber closure has become an intricate part of the pharmaceutical closure system, especially regarding lyophilisation stoppers. Modern day lyophilisation stoppers are required to have a low gas and vapour permeability, low affinity to hold moisture, stability in the halfway-down position and vents which are large enough to allow efficient mass transfer during the lyophilisation process.

Also of importance, the closure must be able to establish and maintain seal integrity before and after crimping the aluminum cap. Along with all of these characteristics, a lyophilisation stopper needs to be universally compatible with different lyophilisation machinery. This article discusses topics associated with lyophilisation closures Ė including compound properties, closure design and coatings.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Douglas Cusato is a Technical Support Manager with Helvoet Pharma. He joined Helvoet Pharma in August 2006 and is responsible for assisting customers with technical issues such as extractables and leachables, rubber formulation, closure design recommendations and closure coatings. During his academic career, Douglas studied protein to substrate interactions and the proteomic and transcriptomic responses of stressed bacteria. He holds a Bachelor degree in Chemistry from Rutgers University, Camden, New Jersey with an emphasis in Biochemistry. In September 2007 he will begin his Masterís degree at Rutgers focusing on Polymer/Material Chemistry. Prior to joining Helvoet Pharma, Douglas was a co-founder of Metabolic Adaptations, a nutrition company specialising in developing athletic sports drinks; he led the product development and packaging division for several years.
spacer
Douglas Cusato
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Companyís novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

The Importance of ADCC in Assessing Clinically Relevant Differences

Sartorius Stedim BioOutsource Ltd

Biosimilars have caused a revolution in the development of biologic drugs. The model for biosimilars is a combination of speed to market and low cost; these are fundamental to any biosimilar development project. The biosimilars pathway to approval is not always without difficulty, biosimilars are still relatively new, and as each new applicant is reviewed we are learning more and more about these molecules.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement